JCJudit Catalán-Aguilar

Judit Catalán-Aguilar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Judit Catalán-Aguilar has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cognitive reserve and memory in temporal lobe epilepsy and caregivers: a comparative pilot study

    by Raquel Ferrer-Ricart, Irene Cano-López, Judit Catalán-Aguilar, Kevin G. Hampel, Paula Tormos-Pons, Teresa Vicente-Hernández, Vicente Villanueva, Esperanza González-Bono

    Drug-resistant epilepsy is characterized by chronic exposure to uncontrollable and unpredictable seizures, resulting in sustained physiological and emotional overload, which supports its conceptual...

  • Open Access

    Affective and Cognitive Vulnerability Under Chronic Stress: Insights From Patients With Left Temporal Lobe Epilepsy and Caregivers

    by Teresa Vicente-Hernández, Irene Cano-López, Judit Catalán-Aguilar, Paula Tormos-Pons, Kevin G. Hampel, Raquel Ferrer-Ricart, Esperanza González-Bono, Vicente Villanueva

    Background: Temporal lobe epilepsy (TLE) is a chronic stress condition characterized by affective and cognitive deficits. This study analyzed differences in affective and cognitive functioning between patients with TLE and another chronically stressed population — caregivers of patients with epilepsy — as well as the relationships between affective and cognitive outcomes. Methods: In this cross-sectional study, 40 adults (20 with left TLE and 20 caregivers; mean age 48.43 ± 8.86 years) underwent a neuropsychological assessment evaluating affectivity, attention, executive function, language, and memory. Results: Patients with TLE and caregivers did not differ in anxiety, depression, attention, executive functions, or visual memory. However, patients with TLE had poorer semantic verbal fluency (p = 0.02), naming (p < 0.0001), short-term verbal recall (p = 0.027), long-term verbal recall with semantic cues (p = 0.005), long-term verbal recognition (p = 0.017), and verbal discriminability (p = 0.001). The group (epilepsy vs. caregiver) significantly moderated the association between depression and long-term verbal recognition (B = –0.12, standard error (SE) = 0.05, p = 0.03, 95% confidence interval (CI) [–0.23, –0.01]), with higher depression scores being associated with poorer verbal recognition in patients with epilepsy (p = 0.001) but not in caregivers (p = 0.74). Conclusions: These findings suggest a specific pattern of verbal dysfunction and increased cognitive vulnerability to depression in patients with TLE, compared to another chronically stressed group. Although the present study cannot determine the mechanisms underlying these associations, the results underscore the clinical relevance of assessing these variables together and may inform the development of tailored interventions.


  • Beyond seizure control: The impact of SEEG ‐guided radiofrequency thermocoagulation on quality of life

    by Judit Catalán‐Aguilar, Rocío Uriel‐Lavin, Adriana Celdrán de Castro, Rebeca Conde, Kevin G. Hampel, Mercedes Garcés‐Sánchez, Paula Tormos‐Pons, Esperanza González‐Bono, Vicente Villanueva, Antonio Gutiérrez

    Objective: Stereoencephalography (SEEG)‐guided radiofrequency thermocoagulation (RF‐TC) is an effective method in improving seizure control. However, as far as we know, no studies have addressed the effectiveness of this treatment in terms of quality of life, despite the global burden of epilepsy. Therefore, the aim of this study is to evaluate the effect of SEEG‐guided RF‐TC on seizure frequency in a cohort of patients with refractory focal epilepsy (RFE), and to explore the relationship between seizure outcomes and changes in quality of life after 1‐year follow‐up. Methods: In this retrospective study, seizure outcomes and quality of life in patients with RFE treated with SEEG‐guided RF‐TC were examined before and after 1 year of intervention, following the presurgical assessment protocol of the Refractory Epilepsy Unit. Results: Thirty‐six patients (44.4% women; mean age 38.78 ± 12.86 years) were included. The mean number of thermocoagulated contacts per patient was 27.63 ± 17.97. Seizures per month decreased significantly after SEEG‐guided RF‐TC (95% CI [−12.50, −5.50], p < 0.001), with 47.2% of patients achieving seizure freedom and 88.6% responding to the treatment after a 1‐year follow‐up. Quality of life improved after intervention in six out of seven of the subscales, as well as in the quality of life composite score. Finally, the seizure reduction rate and seizure frequency after SEEG‐guided RF‐TC predicted changes in the quality of life composite score ( p = 0.047 and p = 0.039, respectively). Significance: Our results show that more favorable seizure outcomes after SEEG‐guided RF‐TC are associated with better quality of life. These findings emphasize the importance of considering a holistic approach when evaluating the effectiveness of epilepsy treatments.

  • Open Access

    Examining the Effectiveness of Neuropsychological Interventions on Cognition in Patients with Epilepsy: A Systematic Review and Meta-Analysis

    by Irene Cano-López, Judit Catalán-Aguilar, Esperanza González-Bono

    This meta-analysis evaluated the effectiveness of neuropsychological interventions in enhancing cognition in patients with epilepsy. The systematic review was conducted under PRISMA guidelines. Of 1363 articles, 25 met the inclusion criteria. Meta-analyses assessing pre-post changes in experimental interventions (i.e., without comparison to control groups) revealed moderate effects on cognition in adults ( g = 0.29; 95% CI = 0.18, 0.40; p < 0.0001), with significant effects for attention ( g = 0.24; 95% CI = 0.06, 0.43; p = 0.0098), immediate memory ( g = 0.34; 95% CI = 0.21, 0.47; p < 0.0001), delayed memory ( g = 0.38; 95% CI = 0.18, 0.57; p < 0.0001), and language ( g = 0.33; 95% CI = 0.06, 0.59; p = 0.0159). In pediatric samples, moderate effects were found on overall cognition ( g = 0.55; 95% CI = 0.22, 0.89; p = 0.0012), with gains in attention ( g = 0.66; 95% CI = 0.15, 1.17; p = 0.01) and working memory ( g = 0.80; 95% CI = −0.05, 1.65; p = 0.06). Comparisons with control groups (i.e., patients without intervention) showed a trend towards positive effects in adults ( g = 0.35; 95% CI = −0.00, 0.71; p = 0.053), with brain training games associated with poorer outcomes ( B = −1.03; SE = 0.52; 95% CI = −2.05, −0.00; p = 0.049). No significant differences were found in pediatric samples ( g = 0.34; 95% CI = −0.22, 0.89; p = 0.24). The findings support the implementation of targeted cognitive interventions in clinical practice, offering evidence-based recommendations.


  • Open Access

    Buffered Cortisol Response to Stress in Patients With Epilepsy and Its Association With Memory and Quality of Life

    by Judit Catalán-Aguilar, Esperanza González-Bono, Vicente Villanueva, Kevin Gil Hampel, Alejandro Lozano-García, Vanesa Hidalgo, Alicia Salvador, Paula Tormos-Pons, Irene Cano-López

    Epilepsy is a chronic stress condition associated with dysregulation in the hypothalamic-pituitary-adrenal axis and cognitive and emotional comorbidities. Therefore, we aimed to examine the acute stress response integrity in adults with epilepsy and its relationship with affectivity, memory, and quality of life (QOL). This hybrid single-blind controlled study involved 3 groups: an experimental group (EG) of patients with epilepsy exposed to the Trier Social Stress Test (TSST) during a neuropsychological assessment; a control group of patients with epilepsy who underwent neuropsychological testing without stress exposure; and a healthy group (HG) also exposed to the TSST. Patients were recruited from the Refractory Epilepsy Unit and randomly assigned to the experimental or control group. Six saliva samples were collected from all groups at consistent intervals to measure cortisol levels. Repeated measures analyses of covariance and Spearman correlations were performed. The sample consisted of 147 participants: 38 patients in the EG (50% women; 38.50 ± 10.92 years), 50 patients in the control group (48% women; 40.82 ± 8.55 years), and 59 individuals in the HG (58% women; 40.82 ± 8.55 years). The EG showed an abolition of the stress response and no differences with those not exposed to the TSST. The HG exhibited the expected cortisol response to stress with a rise in the area under the curve with respect to increase, which contrasts with the decreases observed in both groups of patients (F(2,146) = 9.15, η2 = 0.11) with and without stress (mean difference [MD] = -107.90, 95% CI -176.75 to -39.05, and MD = -89.19, 95% CI -152.81 to -25.56, respectively). Cortisol production in the EG was related to lower seizure frequency (ρ = -0.40, 95% CI -0.66 to -0.08), and better memory retrieval (ρ = 0.43, 95% CI 0.15-0.68) and QOL (ρ = 0.40, 95% CI 0.10-0.65). Patients with epilepsy may exhibit a buffered cortisol response to acute stress. Preservation of this response is associated with better clinical, cognitive, and QOL outcomes. Despite limitations such as the cross-sectional design and sample specificity, these findings could help clarify the underlying mechanisms of stress-epilepsy interaction.


  • Open Access

    Monitoring cognition in people with epilepsy and intellectual disability

    by Judit Catalán-Aguilar, Juri-Alexander Witt, Christoph Helmstaedter


  • Open Access

    Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy

    by Judit Catalán‐Aguilar, Kevin G. Hampel, Irene Cano‐López, Mercedes Garcés, Alejandro Lozano‐García, Paula Tormos‐Pons, Esperanza González‐Bono, Vicente Villanueva

    Objective: Cenobamate is a recently approved antiseizure medication that proved to be safe and effective in randomized controlled trials. However, little is known about its impact on some areas frequently affected by epilepsy. For this reason, we explored the effects of cenobamate on cognitive performance, as well as on negative affectivity and quality of life in a sample of patients with drug‐resistant epilepsy.Methods: Two prospective cohort studies were carried out. In Study 1, 32 patients (22 men and 10 women) underwent a baseline (T0) and a short‐term (T1) neuropsychological assessment after 3 months of cenobamate administration. In Study 2, 22 patients (16 men and 6 women) from the T1 sample also underwent a baseline and a follow‐up evaluation (T2) 6 months after T0.Results: No significant differences were found in cognitive variables, negative affectivity, and quality of life either in Study 1 or Study 2. Similarly, based on the reliable change index, it was found that most patients showed no changes in these variables.Significance: These results suggest that cenobamate is a safe antiseizure medication in terms of cognition, negative affectivity, or quality of life since no adverse events have been found after 3 and 6 months of treatment.Plain Language Summary: Cenobamate is a new antiseizure medication. In patients with epilepsy, cenobamate seems to not affect cognition, anxiety, depression, or quality of life.